Bristol Myers Squibb Company BMY
62.86
1.36
2.21%
as of 25 Sep
- Market cap
- $125.9B
- P/E
- 13.8×
Follow BMY
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Bristol Myers Squibb Company (BMY) Book value per share
Bristol Myers Squibb Company's book value per share at the end of fiscal 2025 was 9.1×, up 12.5% from 8.1× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 10.9×. Over the past ten years it has ranged from 7.2× (fiscal 2017) to 30.3× (fiscal 2019); the current reading is higher than 45% of that period. Bristol Myers Squibb Company ranks 12th of 21 Drug Manufacturers General companies by book value per share.
Book value per share, annual
Annual
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 9.1× | 12.53% |
| FY2024 | 8.1× | (43.27%) |
| FY2023 | 14.3× | (2.45%) |
| FY2022 | 14.6× | (9.88%) |
| FY2021 | 16.2× | (3.37%) |
| FY2020 | 16.8× | (44.67%) |
| FY2019 | 30.3× | 250.50% |
| FY2018 | 8.7× | 20.12% |
| FY2017 | 7.2× | (26.38%) |
| FY2016 | 9.8× | 13.06% |
Quarterly
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 10.9× | 10.81% |
| Mar 2026 | 9.9× | 8.41% |
| Dec 2025 | 9.1× | (0.41%) |
| Sep 2025 | 9.1× | 6.30% |
| 42 more quarters | Free account |
Against its own ten years
Low 7.2×
High 30.3×
Ten-year median
9.8×
Current reading's percentile
45
Book value per share against peers
| Company | Book value per share |
|---|---|
| SNY Sanofi compare | 33.8× |
| AZN AstraZeneca PLC compare | 32.5× |
| NVS Novartis AG compare | 22.0× |
| AMGN Amgen Inc. compare | 21.6× |
| PFE Pfizer Inc. compare | 15.0× |
| GSK GSK PLC Sponsored ADR compare | 11.5× |
| BMY Bristol Myers Squibb Company | 10.9× |
| GILD Gilead Sciences, Inc. compare | 9.4× |
| NVO Novo Nordisk A/S compare | 7.8× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on BMY
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- The full statement